Ostatní
Návod 
I-Mab
IMAB
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
0.9B
Obrat
0B
Zisk
0B
Aktiva
0B
Dluh
0B
ROE
-19%
ROA
-18%
PE
-6
PS
0
Cena 1R
1-7
⌀ Cena
2.39
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
01-04-2026
Poslední dividenda
Profil
I-Mab, klinická biofarmaceutická společnost, objevuje, vyvíjí a komercializuje biologii k léčbě rakoviny a autoimunitních poruch. Vyvíjí se Felzartamab, protilátka CD38, která je ve fázi 1b/2a u pacientů s membránovou nefropatií; Eftansomatropin alfa, dlouhodobě působící lidský růstový hormon, který dokončil klinické studie fáze 3 pro léčbu deficitu pediatrického růstového hormonu; TJ107, rekombinantní lidský IL- 7, který je ve fázi 2 pro léčbu rakoviny související s lymfopenií a onkologickou imunoterapií; a Lemzoparlimab, monoklonální protilátka CD47, která dokončila klinickou studii fáze 2. Mezi jeho produktové kandidáty patří také Enoblituzumab, humanizovaná B7-H3 protilátka, která je ve fázi 2 k léčbě rakoviny hlavy a krku a dalších onkologických onemocnění; Efineptakin, dlouhodobě působící rekombinantní lidský IL- 7, který je ve fázi 2 klinických studií k léčbě lymfopenie a rakovinné imunoterapie; TJ210, monoklonální protilátka proti lidskému C5aR1, která je ve fázi 1 k léčbě rakoviny a autoimunity; Plonmarlimab, monoklonální protilátka GM-CSF proti zánětu a CRS-R příbuzné terapie; Uliledlimab, protilátka CD73, která je ve fázi 2 klinických studií pro léčbu solidních nádorů a onkologii; TJ-L14B, tumor-dependentní T-buněčný engager pro solidní nádory; a TJ-CD4B, tumor-dependentní T buněčný engager pro žaludeční a jiné nádory, a TJ-L1IF, PD-L1/IFN-a protilátkový cytokin fusion protein pro solidní nádory a TJ-C64B, tumor-dependentní T-buněčný engin Touží po rakovině vaječníků a jiných druhů rakoviny. Společnost I-Mab uzavřela dohodu o strategické spolupráci s AbbVie Ireland Unlimited Company, Sinopharm Group Co. Ltd., PT Kalbe Genexine Biologics a Roche Diagnostics. Společnost byla založena v roce 2014 a sídlí v Šanghaji, Čínské lidové republice.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
32
Založení
2020-01-17
Podobné společnosti
$ 6.76
- $ 0.80
$ 5.45
+ $ 0.10
$ 3.15
- $ 0.03
$ 3.00
+ $ 0.12
$ 3.77
- $ 0.09
$ 4.09
- $ 0.03
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 0.00 | 0.00 | 27,644.00 | -221,563.00 | 88,026.00 | 1,542,668.00 | 30,000.00 | 53,781.00 | 11,556.00 | |
| Cost of Revenues | 0.00 | 0.00 | 0.00 | 27,237.00 | 46,432.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 27,644.00 | -248,800.00 | 41,594.00 | 1,542,668.00 | 30,000.00 | 53,781.00 | 11,556.00 |
| Revenue | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,994.50 | 3,994.50 | 9,827.50 | 9,827.50 | |
| Cost of Revenues | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,994.50 | 3,994.50 | 9,827.50 | 9,827.50 |
| Operating Income | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.00 | 0.00 | 114,359.11 | 904,901.00 | 1,212,958.00 | 984,689.00 | 840,415.00 | 426,028.00 | 267,075.00 | |
| Selling General & Admin Expenses | 0.00 | 0.00 | 63,907.82 | 720,271.00 | 899,943.00 | 402,409.00 | 654,553.00 | 66,391.00 | 25,436.00 | |
| Depreciation & Amortization | 5,989.89 | 1,905.00 | 23,949.00 | -537,144.00 | -263,388.00 | 23,136.00 | 46,674.00 | 6,740.00 | 1,634.00 | |
| Total Operating Expenses | 38,163.00 | 375,358.00 | 201,201.51 | 1,625,172.00 | 2,112,901.00 | 1,387,098.00 | 1,494,400.00 | 491,669.00 | 292,511.00 | |
| Operating Income | -38,163.00 | -375,358.00 | -1,236,019.00 | -1,873,972.00 | -2,071,307.00 | 460,967.00 | -1,464,968.00 | -438,638.00 | -280,955.00 |
| Operating Income | TTM | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 182,105.00 | 182,105.00 | 223,218.00 | 223,218.00 | ||
| Selling General & Admin Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 104,013.00 | 104,013.00 | 122,495.50 | 122,495.50 | ||
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | 5,989.89 | 5,987.66 | 5,987.25 | 5,987.25 | 6,335.00 | 335,886.00 | 335,886.00 | ||
| Total Operating Expenses | 7,114.00 | 5,266.00 | 13,371.00 | 12,412.00 | 258,954.12 | 90,620.89 | 360,809.50 | 360,809.50 | 411,373.00 | 411,373.00 | ||
| Operating Income | -7,114.00 | -5,266.00 | -13,371.00 | -12,412.00 | -15,008.00 | -90,620.89 | -282,123.50 | -282,123.50 | -335,886.00 | -335,886.00 |
| Net Income | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 8,318.00 | 54,640.00 | 7,300.31 | 26,908.00 | 21,333.00 | 24,228.00 | 30,570.00 | 4,597.00 | 858.00 | |
| Interest Expense | 0.00 | 0.00 | 101.85 | 9.00 | -2,991.00 | 957.00 | 2,991.00 | 11,695.00 | 5,643.00 | |
| Other Expense | -1,826.00 | 12,627.00 | -229,675.00 | -537,153.00 | -263,388.00 | 22,179.00 | 13,018.00 | 37,527.00 | -17,285.00 | |
| IBT | -39,989.00 | -362,731.00 | -1,465,694.00 | -2,411,125.00 | -2,334,695.00 | 483,146.00 | -1,451,950.00 | -401,111.00 | -298,240.00 | |
| Income Tax Expense | 0.00 | 0.00 | -1,258,926.23 | 697.00 | -3,154.00 | 12,231.00 | 2,893.00 | 1,722.00 | -11,642.00 | |
| Net Income | -38,207.00 | -162,257.00 | -1,465,694.00 | -2,411,822.00 | -2,331,541.00 | 470,915.00 | -1,454,843.00 | -402,833.00 | -298,240.00 |
| Net Income | TTM | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 1,800.00 | 1,872.00 | 2,197.00 | 2,449.00 | 1,921.00 | 709.00 | 10,366.00 | 10,366.00 | 15,147.50 | 15,147.50 | ||
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Other Expense | 1,610.00 | 2,116.00 | 2,527.00 | -8,079.00 | -34,478.23 | 20,639.80 | 16,961.50 | 16,961.50 | -50,512.00 | -50,512.00 | ||
| IBT | -5,504.00 | -3,150.00 | -10,844.00 | -20,491.00 | -49,486.23 | -69,981.09 | -346,449.00 | -346,449.00 | -386,398.00 | -386,398.00 | ||
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | -42,676.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Net Income | -5,504.00 | -3,150.00 | -9,062.00 | -20,491.00 | 25,126.00 | 20,841.97 | -346,449.00 | -346,449.00 | -386,398.00 | -386,398.00 |
| Per Share Data | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $-17.62 | $-31.75 | $-30.69 | $8.07 | $-25.16 | $-9.05 | $-6.70 | |
| EPS Diluted | $0.00 | $0.00 | $-17.61 | $-29.23 | $-30.69 | $6.90 | $-25.16 | $-9.05 | $-6.70 | |
| Shares Outstanding | 81,699.28 | 81,186.09 | 83,192.99 | 75,959.59 | 75,959.59 | 58,329.92 | 57,828.98 | 44,524.52 | 44,524.52 | |
| Diluted Shares Outstanding | 81,699.28 | 81,186.09 | 83,227.76 | 82,516.21 | 75,959.59 | 68,361.59 | 57,828.98 | 44,524.52 | 44,524.52 |
| Per Share Data | TTM | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-4.16 | $-4.16 | $-4.65 | $-4.65 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-4.16 | $-4.16 | $-4.65 | $-4.65 | ||
| Shares Outstanding | 81,699.28 | 81,599.77 | 81,495.84 | 81,495.84 | 81,779.17 | 82,062.49 | 83,214.06 | 83,214.06 | 83,167.89 | 83,167.89 | ||
| Diluted Shares Outstanding | 81,699.28 | 81,599.77 | 81,495.84 | 81,495.84 | 80,931.99 | 80,870.27 | 83,287.64 | 83,287.64 | 83,167.89 | 83,167.89 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 1,104,255.00 | 68,263.00 | 302,097.03 | 3,214,005.00 | 3,523,632.00 | 4,758,778.00 | 1,137,473.00 | 1,588,278.00 | 307,930.00 | |
| Short Term Investments | 403,483.52 | 105,135.00 | 20,204.41 | 235,429.00 | 753,164.00 | 31,530.00 | 32,000.00 | 255,958.00 | 266,245.00 | |
| Total Cash & ST Investments | 1,507,738.52 | 173,398.00 | 2,289,529.00 | 3,449,434.00 | 4,276,796.00 | 4,790,308.00 | 1,169,473.00 | 1,844,236.00 | 574,175.00 | |
| Accounts Receivable | 0.00 | 1,172.00 | 2,534.49 | 80,278.00 | 477,685.00 | 553,356.00 | 55,870.00 | 23,906.00 | 4,101.00 | |
| Inventory | 0.00 | 0.00 | 12,779.86 | -80,278.00 | 27,237.00 | -422,858.00 | -55,870.00 | 0.00 | 0.00 | |
| Other Current Assets | 167,068.70 | 2,123.00 | 31,825.65 | 177,042.00 | 444,604.00 | 422,858.00 | 191,846.00 | 168,719.00 | 113,315.00 | |
| Total Current Assets | 1,674,807.22 | 176,693.00 | 2,336,669.00 | 3,626,476.00 | 4,781,718.00 | 5,343,664.00 | 1,361,319.00 | 2,036,861.00 | 691,591.00 |
| Current Assets | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 165,404.00 | 53,597.00 | 68,263.00 | 79,327.00 | 151,961.00 | 0.00 | 2,141,445.00 | 2,141,445.00 | 2,359,592.00 | 2,359,592.00 | |
| Short Term Investments | 210.00 | 115,025.00 | 105,135.00 | 105,064.00 | 403,484.00 | 0.00 | 143,221.00 | 148,084.00 | 585,913.00 | 585,913.00 | |
| Total Cash & ST Investments | 165,614.00 | 168,622.00 | 173,398.00 | 184,391.00 | 1,507,739.00 | 2,250,825.00 | 2,284,666.00 | 2,289,529.00 | 2,945,505.00 | 2,945,505.00 | |
| Accounts Receivable | 2,026.00 | 4,611.00 | 1,172.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventory | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -17,966.00 | 0.00 | -102,345.00 | 0.00 | |
| Other Current Assets | 0.00 | 0.00 | 2,123.00 | 3,820.00 | 167,068.00 | -2,250,825.00 | 20,116.00 | 47,140.00 | 129,340.00 | 0.00 | |
| Total Current Assets | 167,640.00 | 173,233.00 | 176,693.00 | 188,211.00 | 1,674,807.00 | 0.00 | 2,336,669.00 | 2,336,669.00 | 3,074,845.00 | 3,074,845.00 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 28,238.40 | 3,798.00 | 11,696.39 | 123,966.00 | 158,497.00 | 40,269.00 | 46,504.00 | 27,659.00 | 22,336.00 | |
| Goodwill | 0.00 | 0.00 | 0.00 | 162,574.00 | 162,574.00 | 162,574.00 | 162,574.00 | 162,574.00 | 162,574.00 | |
| Intangible Assets | 0.00 | 0.00 | 16,661.96 | 118,888.00 | 119,666.00 | 120,444.00 | 148,844.00 | 148,844.00 | 148,844.00 | |
| Long-Term Investments | 138,067.30 | 30,824.00 | 1,704.43 | 30,850.00 | 380,342.00 | 664,832.00 | 0.00 | 0.00 | 0.00 | |
| Other Long-Term Assets | 3,371.75 | 1,365.00 | 246,235.23 | 10,911.00 | 26,634.00 | 2,010.00 | 18,331.00 | 0.00 | 0.00 | |
| Total Long-Term Assets | 169,677.45 | 35,987.00 | 276,298.00 | 447,189.00 | 847,713.00 | 990,129.00 | 376,253.00 | 339,077.00 | 333,754.00 | |
| Total Assets | 1,844,484.66 | 212,680.00 | 2,612,967.00 | 4,073,665.00 | 5,629,431.00 | 6,333,793.00 | 1,737,572.00 | 2,375,938.00 | 1,025,345.00 |
| Long-Term Assets | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 3,381.00 | 3,592.00 | 3,798.00 | 3,691.00 | 28,238.00 | 0.00 | 82,911.00 | 82,911.00 | 102,464.00 | 102,464.00 | |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 162,574.00 | 162,574.00 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 118,110.00 | 118,110.00 | 118,499.00 | 118,499.00 | |
| Long-Term Investments | 34,468.00 | 30,824.00 | 30,824.00 | 39,343.00 | 138,067.00 | 0.00 | 12,082.00 | 12,082.00 | 11,411.00 | 11,411.00 | |
| Other Long-Term Assets | 1,219.00 | 1,292.00 | 1,365.00 | 1,437.00 | 3,372.00 | 0.00 | 63,195.00 | 63,195.00 | 41,902.00 | 41,902.00 | |
| Total Long-Term Assets | 39,068.00 | 35,708.00 | 35,987.00 | 44,471.00 | 169,677.00 | 0.00 | 276,298.00 | 276,298.00 | 436,850.00 | 436,850.00 | |
| Total Assets | 206,708.00 | 208,941.00 | 212,680.00 | 232,682.00 | 253,827.00 | 0.00 | 2,612,967.00 | 2,612,967.00 | 3,511,695.00 | 3,511,695.00 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3,920.00 | 67,674.00 | 14,509.00 | |
| Short-Term Debt | 5,355.56 | 816.00 | 7,315.97 | 42,917.00 | 30,669.00 | 8,058.00 | 56,807.00 | 80,000.00 | 99,000.00 | |
| Other Current Liabilities | 96,174.78 | 7,532.00 | 402,916.05 | 608,148.00 | 593,335.00 | 560,558.00 | 531,672.00 | 184,333.00 | 65,832.00 | |
| Current Liabilities | 101,530.33 | 8,454.00 | 411,814.00 | 659,742.00 | 624,004.00 | 576,125.00 | 588,479.00 | 346,158.00 | 195,144.00 |
| Current Liabilities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Short-Term Debt | 853.00 | 835.00 | 816.00 | 753.00 | 737.00 | 0.00 | 51,860.00 | 51,860.00 | 7,898.20 | 29,970.00 | |
| Other Current Liabilities | 6,494.00 | 6,916.00 | 7,532.00 | 11,018.00 | 100,793.00 | 0.00 | 348,740.00 | 359,954.00 | 1,214,821.58 | 633,103.00 | |
| Current Liabilities | 7,347.00 | 7,751.00 | 8,454.00 | 11,771.00 | 101,530.00 | 0.00 | 411,814.00 | 411,814.00 | 663,073.00 | 663,073.00 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 23,413.31 | 3,066.00 | 3,258.61 | 32,069.00 | 81,786.00 | 5,542.00 | 75,691.00 | 67,026.00 | 114,007.00 | |
| Capital Leases | 28,768.87 | 3,882.00 | 6,346.67 | 56,030.00 | 112,455.00 | 13,600.00 | 14,299.00 | 0.00 | 0.00 | |
| Def. Tax Liability | 0.00 | 0.00 | 0.00 | 0.00 | 96,911.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Liabilities | 124,943.64 | 11,520.00 | 894,811.00 | 1,065,339.00 | 1,041,635.00 | 706,648.00 | 3,772,267.00 | 3,331,042.00 | 1,325,140.00 |
| Long-Term Liabilities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 2,628.00 | 2,849.00 | 3,066.00 | 3,028.00 | 3,222.00 | 0.00 | 82,012.00 | 23,099.00 | 20,406.00 | 20,406.00 | |
| Capital Leases | 3,481.00 | 3,684.00 | 3,882.00 | 3,781.00 | 3,959.00 | 0.00 | 44,989.00 | 44,989.00 | 47,728.00 | 47,728.00 | |
| Def. Tax Liability | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -361,788.00 | 0.00 | 64,787.00 | 0.00 | |
| Total Liabilities | 9,975.00 | 10,600.00 | 11,520.00 | 14,799.00 | 17,194.00 | -1,751,578.00 | 894,811.00 | 894,811.00 | 1,064,912.00 | 1,064,912.00 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 138.07 | 19.00 | 18.76 | 132.00 | 126.00 | 114.00 | 6.00 | 6.00 | 6.00 | |
| Retained Earnings | -9,130,390.55 | -1,286,039.00 | -8,327,844.00 | -6,766,655.00 | -4,354,833.00 | -2,023,292.00 | -2,494,207.00 | -1,014,489.00 | -357,860.00 | |
| Comprehensive Income | 293,923.48 | 33,384.00 | 42,080.38 | 216,723.00 | -186,510.00 | -50,793.00 | 70,127.00 | 59,380.00 | 5,691.00 | |
| Total Common Equity | 1,719,541.02 | 201,160.00 | 1,718,156.00 | 3,008,326.00 | 4,587,796.00 | 5,627,145.00 | -2,034,695.00 | -955,104.00 | -299,795.00 |
| Total Common Equity | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 0.00 | 133.00 | 133.00 | 133.00 | 133.00 | |
| Retained Earnings | -1,294,693.00 | -1,289,189.00 | -1,286,039.00 | -1,276,976.00 | -1,256,470.00 | 0.00 | -8,327,844.00 | -8,327,844.00 | -7,634,946.00 | -7,634,946.00 | |
| Comprehensive Income | 37,039.00 | 33,387.00 | 33,384.00 | 41,869.00 | 40,448.00 | 1,751,578.00 | 298,291.00 | 298,291.00 | 376,473.00 | 376,473.00 | |
| Total Common Equity | 196,733.00 | 198,341.00 | 201,160.00 | 217,883.00 | 236,633.00 | 1,751,578.00 | 1,718,156.00 | 1,718,156.00 | 2,446,783.00 | 2,446,783.00 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 28,768.87 | 3,882.00 | 18,885.53 | 74,986.00 | 112,455.00 | 13,600.00 | 132,498.00 | 147,026.00 | 213,007.00 | |
| Book Value | 1,719,541.02 | 201,160.00 | 1,718,156.00 | 3,008,326.00 | 4,587,796.00 | 5,627,145.00 | -2,034,695.00 | -955,104.00 | -299,795.00 |
| Other | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Book Value | 196,733.00 | 198,341.00 | 201,160.00 | 217,883.00 | 236,633.00 | 1,751,578.00 | 1,718,156.00 | 1,718,156.00 | 2,446,783.00 | 2,446,783.00 |
| Cash Flow From Operating Activities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -1,465,694.00 | -49,696.00 | -206,767.77 | -2,507,317.00 | -2,331,541.00 | 470,915.00 | -1,451,950.00 | -402,833.00 | -298,240.00 | |
| Depreciation & Amortization | 0.00 | 978.00 | 7,436.31 | 63,816.00 | 34,136.00 | 23,136.00 | 15,634.00 | 6,740.00 | 1,634.00 | |
| Stock-Based Compensation | 193,002.00 | -1,949.00 | 193,002.00 | 357,148.00 | 608,609.00 | 493,464.00 | 366,895.00 | 3,520.00 | 7,039.00 | |
| Change Working Capital | 0.00 | -2,811.00 | -44,773.86 | 552,064.00 | 394,520.00 | -240,642.00 | 184,789.00 | 147,928.00 | 25,041.00 | |
| Change In Accounts Receivable | 0.00 | 0.00 | 0.00 | 33,081.00 | 97,417.00 | -130,498.00 | 0.00 | 0.00 | 0.00 | |
| Change In Accounts Payable | 0.00 | 0.00 | 0.00 | 0.00 | 107,849.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Change In Inventories | 0.00 | 0.00 | 0.00 | 27,237.00 | -27,237.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-cash Items | 1,272,692.00 | 809.00 | -1,253,846.68 | 431,484.00 | 321,183.00 | -313,315.00 | 23,039.00 | 38,967.00 | 3,835.00 | |
| Cash from Operations | 0.00 | 0.00 | -1,304,950.00 | -1,102,805.00 | -973,093.00 | 433,558.00 | -867,982.00 | -280,705.00 | -252,157.00 |
| Cash Flow From Operating Activities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -13,267.54 | -22,868.69 | -66,144.00 | -143,797.64 | 180,071.64 | 20,841.97 | -346,449.00 | -346,449.00 | -386,398.00 | -386,398.00 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stock-Based Compensation | 2,149.17 | 2,177.97 | 11,321.00 | 2,105.28 | 8,263.03 | -13,718.95 | 29,094.00 | 29,094.00 | 67,407.00 | 67,407.00 | |
| Change Working Capital | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Change In Accounts Receivable | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Change In Accounts Payable | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Change In Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-cash Items | 11,118.37 | 20,690.72 | 54,823.00 | 141,692.36 | -188,334.67 | -7,123.02 | 317,355.00 | 317,355.00 | 318,991.00 | 318,991.00 | |
| Cash from Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow From Investing Activities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | 0.00 | -48.00 | -11,351.00 | -45,830.00 | -29,932.00 | -8,008.00 | -12,241.00 | -14,409.00 | -20,327.00 | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | -6,000.00 | -257,651.00 | 0.00 | 0.00 | 93,335.00 | |
| Investments | 0.00 | -245,863.00 | 0.00 | -7,407,332.00 | -10,173,314.00 | -2,491,991.00 | -134,000.00 | -30,000.00 | -369,000.00 | |
| Sales of Investment | 0.00 | 109,834.00 | 0.00 | 7,911,518.00 | 9,482,040.00 | 2,503,749.00 | 358,703.00 | 53,909.00 | 138,327.00 | |
| Other Investing Activities | 0.00 | 0.00 | 113,866.00 | 26.00 | 0.00 | 52,000.00 | 0.00 | 0.00 | 0.00 | |
| Cash from Investing | 0.00 | 0.00 | 102,515.00 | 458,382.00 | -727,206.00 | -201,901.00 | 212,462.00 | 9,500.00 | -157,665.00 |
| Cash Flow From Investing Activities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Sales of Investment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash from Investing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow From Financing Activities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.00 | 0.00 | 9,864.71 | 0.00 | 0.00 | -50,000.00 | -80,000.00 | -99,000.00 | 0.00 | |
| Debt Issued | 58,886.00 | -15,003.53 | -46,235.75 | -37,469.00 | 98,855.00 | -68,898.00 | 65,472.00 | 33,019.00 | 213,007.00 | |
| Issuance of Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,543,614.00 | 0.00 | 0.00 | 0.00 | |
| Repurchase of Common Stock | 0.00 | -335.00 | -9,189.83 | -21,249.00 | 0.00 | -34,859.00 | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9,321.00 | -5,283.00 | 0.00 | 0.00 | |
| Other Financing Activities | 0.00 | 0.00 | 62,850.29 | 63,606.00 | 593,924.00 | -8,953.00 | 237,992.00 | 1,578,669.00 | 758,585.00 | |
| Cash from Financing | 0.00 | 0.00 | 7,572.00 | 42,357.00 | 593,924.00 | 3,440,481.00 | 152,709.00 | 1,479,669.00 | 758,585.00 |
| Cash Flow From Financing Activities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Debt Issued | -203.00 | -198.00 | 101.00 | -178.00 | 3,959.00 | -133,872.00 | 80,803.00 | -24,629.00 | 27,322.00 | -24,610.00 | |
| Issuance of Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash from Financing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash position | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -225,789.71 | -242,404.00 | -1,110,411.00 | -212,863.00 | -1,235,146.00 | 3,565,495.00 | -487,648.00 | 1,268,218.00 | 348,631.00 | |
| Closing Cash Balance | 0.00 | 498,251.00 | 2,200,358.00 | 3,310,769.00 | 3,523,632.00 | 4,758,778.00 | 1,193,283.00 | 1,680,931.00 | 412,713.00 |
| Cash position | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -225,789.71 | 0.00 | |
| Closing Cash Balance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 328,547.71 | 0.00 |
| Free Cash Flow | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -52,717.00 | -1,316,301.00 | -1,148,635.00 | -1,003,025.00 | 425,550.00 | -880,223.00 | -295,114.00 | -272,484.00 | |
| Real Free Cash Flow | -193,002.00 | -50,768.00 | -1,509,303.00 | -1,505,783.00 | -1,611,634.00 | -67,914.00 | -1,247,118.00 | -298,634.00 | -279,523.00 |
| Free Cash Flow | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Real Free Cash Flow | -2,149.17 | -2,177.97 | -11,321.00 | -2,105.28 | -8,263.03 | 13,718.95 | -29,094.00 | -29,094.00 | -67,407.00 | -67,407.00 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -6.2 | 22911.2 | -1.4 |
| P/S | 0 | 1101.2 | 9.4 |
| P/B | 1.2 | 303.4 | 5.2 |
| P/FCF | -13.3 | 3281.6 | -1.5 |
| Market cap | $0.9 | $0.4 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 1.7 % | 3 % | 0 % |
| Debt to Income | -9.1 % | -10.7 % | 0 % |
| Debt to Free cash flow | -19.6 % | -981.5 % | 0 % |
| Interest expense percentage | 0 % | -0.1 % | 44.7 % |
| Current ratio | 22.8 | 8.2 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -19.4 % | -65.6 % | 0 % |
| ROA | -18.5 % | -45 % | 0 % |
| CapEx to Revenue | 0 % | 15.3 % | 0 % |
| RaD to Revenue | 0 % | 2003.9 % | 0 % |
| ROEM | 0.0 | 17832.6 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 0 % | 87.1 % | 68.7 % |
| Operating margin | 0 % | -2707 % | 35.5 % |
| Net margin | 0 % | -2523.5 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 0 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 81.7 mil | 11.8 mld |
| Employee count | 0.0 tis | 0.2 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
